El interés en corto de DeFi Development Corp da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de DeFi Development Corp. Los datos de interés en corto se actualizan cada dos semanas.

DeFi Development Corp (NASDAQ:JNVR) Bolsa, Informe de interés en corto

Janover

Cryptocurrency,Concept.,A,Macro,Shot,Of,Solana,Cryptocurrency,Coin,In

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

JNVR

Solana sube 43 % en 30 días. Airdrop del token SNS, apoyo institucional y posible impacto de la Fed marcan el rumbo de SOL.

Solana (SOL) sube 43% en un mes: nuevo token SNS, apoyo institucional y posible rally tras la Fed

DeFi Development Corp

Macro Economic Events

News

Politics

Global

Economics

General

U.S. Commerce Secretary Lutnick Says Our 10% Tariff Stays On; UK Government Nationalized British Steel As Part Of This Deal; UK Will Announce It Will Buy $10B Worth Of Boeing Planes

WIIM

PAAS

Pan American Silver shares are trading higher after the company reported better-than-expected Q1 financial results.

CPRX

Catalyst Pharmaceuticals shares are trading lower after the company issued FY25 sales guidance below estimates.

Goldman Sachs analyst George Kelly maintains H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) with a Sell and raises the price target from $49 to $54.

Price Target

Analyst Ratings

Goldman Sachs Maintains Sell on H&R Block, Raises Price Target to $54

President Trump Says U.S.-UK Trade Deal Will Lead To The Creation Of An Aluminum And Steel Trading Zone, And A Secure Pharmaceutical Supply Chain

BlackBerry shares are trading higher after the company announced a share buyback program where it will repurchase 27.85 million shares.

Goldman Sachs analyst Will Nance maintains Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Neutral and raises the price target from $10 to $12.

FLYW

Goldman Sachs Maintains Neutral on Flywire, Raises Price Target to $12

President Trump Says From UK Trade Deal, U.S. Will Raise $6B In External Revenue From 10% Tariffs, $5B In New Export Opportunities

Occidental Petroleum Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) shares are trading higher premarket on Thursday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45266538/occidental-announces-first-quarter-2025-results" rel="noreferrer noopener">reported first-quarter results on Wednesday</a>.
Adjusted EPS of 87 cents&nbsp;per share, which beat the <a href="https://www.benzinga.com/earnings">analyst consensus estimate of&nbsp;77&nbsp;cents</a>.
Quarterly revenue came in at&nbsp;$6.84 billion, which missed the analyst consensus estimate of&nbsp;$6.89 billion.
Total company production of 1,391 thousand barrels of oil equivalent per day (Mboed), with average production for Permian, Rockies &amp; Other Domestic, Gulf of America, and International coming in at 754 Mboed, 292 Mboed, 121 Mboed, and 224 Mboed, respectively.
Operating cash flow stood at $2.1 billion, and capital spending of $1.9 billion in the quarter.
Occidental disclosed year-to-date debt repayments of $2.3 billion. Roughly $1.3 billion worth of divestitures closed in the first quarter of 2025.
Dividend: On May 1, the company disclosed a dividend of 24 cents per share, payable July 15, to shareholders of record as of June 10, 2025.
CEO Vicki Hollub said the company continues to reduce debt.
Outlook: The company sees production of 1,377 &#8211; 1,417 Mboed in the second quarter and 1,390 &#8211; 1,440 Mboed <a target="_blank" href="https://www.oxy.com/siteassets/documents/investors/quarterly-earnings/oxy1q25conferencecallslides.pdf" rel="noreferrer noopener">in </a>FY25.
The company slashed the mid-point of 2025 capital guidance by $200 million and domestic operating costs by $150 million, on continued operational efficiency gains and schedule optimization <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">in the Permian and Gulf of America</a>.
The company sees net capital expenditure outlook of $7.2 billion &#8211; $7.4 billion in FY25.
Investors can gain exposure to the stock via&nbsp;Texas Capital Funds Trust Texas Capital Texas Oil Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OILT#NYSE">OILT</a>) and First Trust Nasdaq Oil &amp; Gas ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXN#NASDAQ">FTXN</a>).
Price Action: OXY shares are up 4.56% at $40.79 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45224883/oil-soars-above-59-as-middle-east-airstrikes-jolt-markets" target="_blank" rel="noreferrer noopener">Oil Soars Above $59 As Middle East Airstrikes Jolt Markets</a></li>
</ul>
Image: Shutterstock

Earnings

Equities

Large Cap

Guidance

Movers

FTXN

OILT

Occidental Beats Q1 Profit Forecast, Slashes Debt By $2.3 Billion Year-To-Date

COLD

Americold Realty Trust shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 FFO guidance.

Goldman Sachs analyst Eric Sheridan maintains Fiverr Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) with a Buy and raises the price target from $41 to $47.

FVRR

Goldman Sachs Maintains Buy on Fiverr Intl, Raises Price Target to $47

BROS

Dutch Bros shares are trading higher after Baird raised its price target on the stock from $66 to $72.

DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company") announced today the purchase of 20,473 Solana ("SOL") valued at approximately $2.97 million. This marks the Company's ninth Solana purchase under its digital asset treasury strategy. Following the transaction, DeFi Development Corp. now holds a total of 420,690 SOL, valued at approximately $61.9 million, inclusive of staking rewards.
Below is a summary of DeFi Dev Corp's current SOL position and key per-share metrics as of May 08, 2025:
<ul>
<li>Total SOL Held: 420,690</li>
<li>Total SOL Held (USD): approximately $61.9 million</li>
<li>Total Shares Outstanding: 2,011,887</li>
<li>SOL per Share ("SPS"): 0.209</li>
<li>SPS (USD): $30.78</li>
</ul>
As with all previously purchased tokens, the most recently purchased SOL will be held long-term and staked to a variety of validators, including DeFi Dev Corp.'s own Solana validators to generate native yield.

DFDV

DeFi Development Purchases 20,473 Solana Valued At About $2.97M

Goldman Sachs analyst Eric Sheridan maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Neutral and raises the price target from $135 to $155.

Goldman Sachs Maintains Neutral on Electronic Arts, Raises Price Target to $155

MTCH

Match Group shares are trading lower after the company reported a Q1 EPS miss and announced a 13% reduction in its workforce.

EPAM Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) reported <a href="https://www.benzinga.com/pressreleases/25/05/n45279186/epam-reports-results-for-first-quarter-2025-and-raises-full-year-revenue-outlook" target="_blank" rel="noreferrer noopener">first-quarter</a> 2025 results on Thursday. Its sales grew 11.7% year-over-year to $1.302 billion, beating the analyst consensus estimate of $1.28 billion.
On an organic constant currency basis, revenue increased by 1.4% YoY.
Adjusted EPS of $2.41 is down from $2.56 a year ago, but beat the consensus <a href="https://www.benzinga.com/earnings">estimate of $2.27</a>.
Adjusted operating income for the quarter reached $175.8 million, up 1.2% YoY, and the margin stood at 13.5%, down from 14.9% YoY.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45285797/forget-rate-cuts-this-year-bank-of-america-warns-after-powells-hawkish-tone">Forget Rate Cuts This Year, Bank Of America Warns After Powell&#8217;s Hawkish Tone</a>
The company's operating cash flow for the first quarter dropped to $24.2 million from $129.9 million year over year. Total cash fell 8.7% to $1.179 billion from $1.290 billion at year-end 2024.
EPAM repurchased 796,000 shares for $160 million in Q1 2025, with $277 million still authorized.
Total headcount reached ~61,700, including ~55,600 delivery professionals, up 0.9% since December 2024.
Second-quarter Outlook: EAPM expects revenue of $1.325 billion to $1.340 billion versus an estimated $1.30 billion, and adjusted EPS of $2.56 to $2.64 versus the $2.47 consensus.
2025 Outlook Raised: Revenue growth raised to 11.5% to 14.5% (or 2.0% to 5.0% organic, constant currency). The company now expects Sales Guidance of $5.27 billion to $5.41 billion (prior from $5.20 billion to $5.39 billion) versus the $5.27 billion consensus.
The company expects Adjusted EPS of $10.70 to $10.95 (prior $10.45 to $10.75) versus the consensus of $10.50. It sees GAAP operating margin at 9.0% to 10% and non-GAAP at 14.5% to 15.5%.
EPAM narrowed its GAAP EPS guidance from $6.78 to 7.08 to $6.78 to $7.00, compared to the $6.88 consensus.
Additionally, EPAM <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45279231/epam-announces-planned-leadership-succession" rel="noreferrer noopener">announced</a> that founder and CEO Arkadiy Dobkin will become Executive Chairman on September 1, 2025, with Balazs Fejes appointed as the new President and CEO to lead the company's next growth phase.
Price Action: EPAM shares are trading higher by 13.7% to $180.98 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45288753/google-at-staggering-42-discount-to-sp-500-after-150-billion-value-dive">Google At Staggering 42% Discount To S&amp;P 500 After $150 Billion Value Dive</a></li>
</ul>
Photo by Jobs 51 via Shutterstock

Tech

EPAM

EPAM Soars On Strong Q1 Earnings, Raised Guidance

DHI Group shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and issued FY25 sales guidance with its midpoint above estimates.

Koppers Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) is preparing to release its quarterly earnings on Friday, 2025-05-09. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Koppers Hldgs to report an earnings per share (EPS) of $0.56.
The market awaits Koppers Hldgs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.14 in the last quarter, leading to a 0.48% drop in the share price on the following day.
Here's a look at Koppers Hldgs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.91</td>
<td>1.30</td>
<td>1.27</td>
<td>0.67</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.77</td>
<td>1.37</td>
<td>1.36</td>
<td>0.62</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716541_0.png" alt="eps graph" />
<h3>Tracking Koppers Hldgs's Stock Performance</h3>
Shares of Koppers Hldgs were trading at $25.04 as of May 07. Over the last 52-week period, shares are down 41.83%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Koppers Hldgs</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Koppers Hldgs.
Koppers Hldgs has received a total of 2 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $64.0, the consensus suggests a potential 155.59% upside.
<h3>Comparing Ratings with Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of AdvanSix, Orion and Mativ Holdings, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for AdvanSix, with an average 1-year price target of $30.5, suggesting a potential 21.81% upside.</li>
<li>Analysts currently favor an Buy trajectory for Orion, with an average 1-year price target of $17.33, suggesting a potential 30.79% downside.</li>
<li>Analysts currently favor an Buy trajectory for Mativ Holdings, with an average 1-year price target of $10.0, suggesting a potential 60.06% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for AdvanSix, Orion and Mativ Holdings, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koppers Hldgs</td>
<td>Outperform</td>
<td>-7.05%</td>
<td>$83.60M</td>
<td>-2.00%</td>
</tr>
<tr>
<td>AdvanSix</td>
<td>Neutral</td>
<td>12.16%</td>
<td>$53.47M</td>
<td>2.98%</td>
</tr>
<tr>
<td>Orion</td>
<td>Buy</td>
<td>-7.26%</td>
<td>$89.30M</td>
<td>3.62%</td>
</tr>
<tr>
<td>Mativ Holdings</td>
<td>Buy</td>
<td>1.39%</td>
<td>$77.60M</td>
<td>0.17%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Koppers Hldgs ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages indicating a decline. However, it ranks in the middle for Return on Equity. Overall, Koppers Hldgs is positioned lower compared to its peers in terms of financial performance metrics.
<h3>Delving into Koppers Hldgs's Background</h3>
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.
<h3>Koppers Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Koppers Hldgs faced challenges, resulting in a decline of approximately -7.05% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Koppers Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.14% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Koppers Hldgs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.0%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.53%, the company showcases effective utilization of assets.
Debt Management: Koppers Hldgs's debt-to-equity ratio surpasses industry norms, standing at 2.09. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/KOP/earnings">To track all earnings releases for Koppers Hldgs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Koppers Hldgs

Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) will release its quarterly earnings report on Friday, 2025-05-09. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Kymera Therapeutics to report an earnings per share (EPS) of $-0.90.
The announcement from Kymera Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.09, leading to a 3.64% increase in the share price on the subsequent day.
Here's a look at Kymera Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.79</td>
<td>-0.84</td>
<td>-0.68</td>
<td>-0.73</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.88</td>
<td>-0.82</td>
<td>-0.58</td>
<td>-0.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>1.0%</td>
<td>4.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716529_0.png" alt="eps graph" />
<h3>Kymera Therapeutics Share Price Analysis</h3>
Shares of Kymera Therapeutics were trading at $29.11 as of May 07. Over the last 52-week period, shares are down 21.85%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Kymera Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Kymera Therapeutics.
A total of 2 analyst ratings have been received for Kymera Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $56.0, suggesting a potential 92.37% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Kiniksa Pharmaceuticals, Twist Bioscience and Travere Therapeutics, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Kiniksa Pharmaceuticals, with an average 1-year price target of $39.67, suggesting a potential 36.28% upside.</li>
<li>Analysts currently favor an Buy trajectory for Twist Bioscience, with an average 1-year price target of $44.0, suggesting a potential 51.15% upside.</li>
<li>Analysts currently favor an Buy trajectory for Travere Therapeutics, with an average 1-year price target of $37.9, suggesting a potential 30.2% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for Kiniksa Pharmaceuticals, Twist Bioscience and Travere Therapeutics, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amicus Therapeutics</td>
<td>Buy</td>
<td>13.45%</td>
<td>$113.55M</td>
<td>-11.19%</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals</td>
<td>Buy</td>
<td>72.54%</td>
<td>$76.13M</td>
<td>1.91%</td>
</tr>
<tr>
<td>Twist Bioscience</td>
<td>Buy</td>
<td>23.23%</td>
<td>$46.03M</td>
<td>-8.78%</td>
</tr>
<tr>
<td>Travere Therapeutics</td>
<td>Buy</td>
<td>97.54%</td>
<td>$77.05M</td>
<td>-89.72%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Kymera Therapeutics ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit and Return on Equity.
<h3>Discovering Kymera Therapeutics: A Closer Look</h3>
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
<h3>Kymera Therapeutics: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Kymera Therapeutics's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -84.56% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Kymera Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -956.88%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Kymera Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -8.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.03%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Kymera Therapeutics's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/KYMR/earnings">To track all earnings releases for Kymera Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KYMR

What's Next: Kymera Therapeutics's Earnings Preview

Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is gearing up to announce its quarterly earnings on Friday, 2025-05-09. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Embecta will report an earnings per share (EPS) of $0.67.
Investors in Embecta are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.21, which was followed by a 1.75% drop in the share price the next day.
Here's a look at Embecta's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.36</td>
<td>0.46</td>
<td>0.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.65</td>
<td>0.45</td>
<td>0.74</td>
<td>0.67</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>10.0%</td>
<td>7.000000000000001%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716520_0.png" alt="eps graph" />
<h3>Market Performance of Embecta's Stock</h3>
Shares of Embecta were trading at $12.47 as of May 07. Over the last 52-week period, shares are down 9.69%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/EMBC/earnings">To track all earnings releases for Embecta visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EMBC

A Peek at Embecta's Future Earnings

Press Releases

DeFi Development Corporation to Host X Spaces Event with Industry Leaders: "Scaling Solana: Builders, Backers, & Believers"

DeFi Development Corporation Appoints John Han as Chief Financial Officer

DeFi Development Corporation Adds $9.9M in Solana to Treasury

DeFi Development Corp. Announces $24 Million Private Placement to Accelerate Solana Accumulation Strategy

DeFi Development Corp. Announces Ticker Symbol Change to "DFDV"

DeFi Dev Corp. Advances Solana Treasury Strategy with Validator Business Acquisition

DeFi Development Corp. Adds $11.2M in Solana to Treasury

DeFi Development Corp. Announces Seven-For-One Stock Split

Financing

DeFi Development Corp. Announces Closing of $24 Million Private Placement

DeFi Development Corp. Purchases 20,473 Solana (SOL), Bringing Treasury Holdings to 420,690 SOL

AMBR

Comments

DeFi Development Corp

Interés en corto

DeFi Development Corp (NASDAQ:JNVR) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL